The survival benefit for patients with EGFR protein expression–positive tumors treated with gefitinib (HR, 0.77; 95% CI, 0.56 to 1.08; P = .126) was slightly greater than for the overall study population (Table 1), with no evidence of a survival benefit of gefitinib to patients with EGFR protein expression–negative tumors (HR, 1.57; 95% CI, 0.86 to 2.87; P = .140). EGFR protein expression–positive patients also seemed to achieve better response rates (8.2% v 1.5%) than EGFR protein expression–negative patients (Table 3).